title: Phase II trial of etoposide, doxorubicin, and cisplatin combination in advanced measurable gastric cancer. An Eastern Cooperative Oncology Group study.
abstract: A phase II study was performed to determine the efficacy and toxicity of the etoposide, doxorubicin, cisplatin (EAP) regimen in the treatment of patients with advanced measurable gastric cancer in a multi-institutional cooperative group setting. Thirty-one evaluable patients with advanced measurable gastric adenocarcinoma were treated with etoposide 120 mg/m2 on days 3, 4, and 5, doxorubicin 20 mg/m2 on days 1 and 8, and cisplatin 40 mg/m2 on days 2 and 9. The treatment was repeated every 28 days. Objective responses were seen in 7 (23%) patients, all achieving partial remissions. Median survival was 9 months for the entire group. Toxicity was mostly hematologic, with grade 3 leukopenia in 26% and grade 4 leukopenia in 55% of the patients. There were 4 treatment-related deaths that were attributable to severe leukopenia and sepsis. Because of the high toxicity and moderate response rate, this regimen is not superior to other less toxic regimens and cannot be recommended for the treatment of advanced gastric cancer outside of an investigational protocol.
authors.affiliation: University of Health Sciences, Chicago Medical School, Illinois, USA.
authors.forename: J L
authors.initials: JL
authors.lastname: Clark
authors.forename: O
authors.initials: O
authors.lastname: Küçük
authors.forename: D S
authors.initials: DS
authors.lastname: Neuberg
authors.forename: A B
authors.initials: AB
authors.lastname: Benson
authors.forename: S G
authors.initials: SG
authors.lastname: Taylor
authors.forename: K J
authors.initials: KJ
authors.lastname: Pandya
authors.forename: E G
authors.initials: EG
authors.lastname: Mansour
authors.forename: H O
authors.initials: HO
authors.lastname: Douglass
authors.forename: D G
authors.initials: DG
authors.lastname: Haller
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary*; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D013274:Stomach Neoplasms / Q000188:drug therapy*; D016019:Survival Analysis
chemical_list: D005047:Etoposide; D004317:Doxorubicin; D002945:Cisplatin